51 research outputs found
Bioinspired Magneto-optical Bacteria
âTwo-in-oneâ magneto-optical bacteria have been produced using the probiotic Lactobacillus fermentum for the first time. We took advantage of two features of bacteria to synthesize this novel and bifunctional nanostructure: their metal-reducing properties, to produce gold nanoparticles, and their capacity to incorporate iron oxide nanoparticles at their external surface. The magneto-optical bacteria survive the process and behave as a magnet at room temperature.This work was funded by Biosearch S.A. (POSTBIO project-Agency for Innovation and Development of Andalucia IDEA) and by MINECO and FEDER (project CTQ2012-32236)
Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol)
<p>Abstract</p> <p>Background</p> <p>A common and potentially life-threatening complication of the treatment of childhood cancer is infection, which frequently presents as fever with neutropenia. The standard management of such episodes is the extensive use of intravenous antibiotics, and though it produces excellent survival rates of over 95%, it greatly inconveniences the three-fourths of patients who do not require such aggressive treatment. There have been a number of studies which have aimed to develop risk prediction models to stratify treatment. Individual participant data (IPD) meta-analysis in therapeutic studies has been developed to improve the precision and reliability of answers to questions of treatment effect and recently have been suggested to be used to answer questions regarding prognosis and diagnosis to gain greater power from the frequently small individual studies.</p> <p>Design</p> <p>In the IPD protocol, we will collect and synthesise IPD from multiple studies and examine the outcomes of episodes of febrile neutropenia as a consequence of their treatment for malignant disease. We will develop and evaluate a risk stratification model using hierarchical regression models to stratify patients by their risk of experiencing adverse outcomes during an episode. We will also explore specific practical and methodological issues regarding adaptation of established techniques of IPD meta-analysis of interventions for use in synthesising evidence derived from IPD from multiple studies for use in predictive modelling contexts.</p> <p>Discussion</p> <p>Our aim in using this model is to define a group of individuals at low risk for febrile neutropenia who might be treated with reduced intensity or duration of antibiotic therapy and so reduce the inconvenience and cost of these episodes, as well as to define a group of patients at very high risk of complications who could be subject to more intensive therapies. The project will also help develop methods of IPD predictive modelling for use in future studies of risk prediction.</p
ĐĄŃŃŃĐșŃŃŃĐ° Đž ŃĐ°ŃŃĐŸŃĐ° ŃĐŸĐżŃŃŃŃĐČŃŃŃĐžŃ Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč Đž ŃĐČŃĐ·Đ°ĐœĐœŃŃ Ń ĐœĐžĐŒĐž ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃŃ ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč: ĐœĐ°ŃĐžĐŸĐœĐ°Đ»ŃĐœĐŸĐ” ĐœĐ°Đ±Đ»ŃĐŽĐ°ŃДлŃĐœĐŸĐ” ĐŒĐœĐŸĐłĐŸŃĐ”ĐœŃŃĐŸĐČĐŸĐ” ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐ” STOPRISK
ĐĐйУĐĐĐŹĐĐХйЏ: ĐŃĐ”ĐœĐșĐ° ŃĐžŃĐșĐ° Đž ĐČŃĐŽĐ”Đ»Đ”ĐœĐžĐ” ĐłŃŃĐżĐżŃ ĐżĐ°ŃĐžĐ”ĐœŃĐŸĐČ Ń ĐČŃŃĐŸĐșĐŸĐč ĐČĐ”ŃĐŸŃŃĐœĐŸŃŃŃŃ ŃĐ°Đ·ĐČĐžŃĐžŃ ĐœĐ”Đ±Đ»Đ°ĐłĐŸĐżŃĐžŃŃĐœĐŸĐłĐŸ ĐžŃŃ
ĐŸĐŽĐ°Â â ĐŸŃĐœĐŸĐČĐ° ŃŃŃĐ”ĐșŃĐžĐČĐœĐŸĐč ĐżŃĐŸŃОлаĐșŃĐžĐșĐž ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃŃ
ĐœĐ”Đ±Đ»Đ°ĐłĐŸĐżŃĐžŃŃĐœŃŃ
ŃĐŸĐ±ŃŃĐžĐč. ĐŠĐĐĐŹ ĐĐĄĐĄĐĐĐĐĐĐĐĐĐŻ: ĐŸĐżŃДЎДлОŃŃ ŃŃŃŃĐșŃŃŃŃ Đž ŃĐ°ŃŃĐŸŃŃ ŃĐŸĐżŃŃŃŃĐČŃŃŃĐžŃ
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč ĐČ ĐżŃĐ”ĐŽĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃĐč пДŃĐžĐŸĐŽ Đž Đ°ŃŃĐŸŃООŃĐŸĐČĐ°ĐœĐœŃĐ” Ń ĐœĐžĐŒĐž ĐœĐ”Đ±Đ»Đ°ĐłĐŸĐżŃĐžŃŃĐœŃĐ” ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃĐ” ĐžŃŃ
ĐŸĐŽŃ. ĐĐĐąĐĐ ĐĐĐĐ« Đ ĐĐĐąĐĐĐ«: ĐŃĐŸĐČĐ”ĐŽĐ”Đœ Đ°ĐœĐ°Đ»ĐžĐ· ĐżĐŸĐșĐ°Đ·Đ°ŃДлДĐč 8241 паŃĐžĐ”ĐœŃĐ° Đ±Đ°Đ·Ń STOPRISK, ĐŸĐżĐ”ŃĐžŃĐŸĐČĐ°ĐœĐœŃŃ
ĐœĐ° ĐŸŃĐłĐ°ĐœĐ°Ń
бŃŃŃĐœĐŸĐč ĐżĐŸĐ»ĐŸŃŃĐž Đž ĐŒĐ°Đ»ĐŸĐłĐŸ ŃĐ°Đ·Đ° Đ·Đ° пДŃĐžĐŸĐŽ Ń 1 ОŃĐ»Ń 2019 г. ĐżĐŸ 30 апŃĐ”Đ»Ń 2022 г. Đ ĐĐĐŁĐĐŹĐąĐйЫ: ĐĄĐŸĐżŃŃŃŃĐČŃŃŃОД Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžŃ ĐČŃŃŃĐ”ŃалОŃŃ Ń 4638 паŃĐžĐ”ĐœŃĐŸĐČ (56,3 %), ĐżŃĐž ŃŃĐŸĐŒ ĐŸĐŽĐœĐŸ Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐ” ĐœĐ°Đ±Đ»ŃЎалО Ń 1872 паŃĐžĐ”ĐœŃĐŸĐČ (22,7 %), ŃĐŸŃĐ”ŃĐ°ĐœĐžĐ” ĐŽĐČŃŃ
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč â Ń 1383 паŃĐžĐ”ĐœŃĐŸĐČ (16,8 %), ŃŃĐ”Ń
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč â Ń 814 паŃĐžĐ”ĐœŃĐŸĐČ (9,9 %), ŃĐ”ŃŃŃĐ”Ń
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč â Ń 395 паŃĐžĐ”ĐœŃĐŸĐČ (4,8 %), Đ±ĐŸĐ»Đ”Đ” 4 â Ń 170 паŃĐžĐ”ĐœŃĐŸĐČ (2,0 %). ĐĐ°ĐžĐ±ĐŸĐ»Đ”Đ” ŃĐ°ŃŃĐŸ ĐČŃŃŃĐ”ŃалОŃŃ ĐłĐžĐżĐ”ŃŃĐŸĐœĐžŃĐ”ŃĐșĐ°Ń Đ±ĐŸĐ»Đ”Đ·ĐœŃ â 48,2 %, Ń
ŃĐŸĐœĐžŃĐ”ŃĐșĐ°Ń ŃĐ”ŃĐŽĐ”ŃĐœĐ°Ń ĐœĐ”ĐŽĐŸŃŃĐ°ŃĐŸŃĐœĐŸŃŃŃ (20,7 %), ĐžŃĐ”ĐŒĐžŃĐ”ŃĐșĐ°Ń Đ±ĐŸĐ»Đ”Đ·ĐœŃ ŃĐ”ŃĐŽŃĐ° (19,3 %). ĐалОŃОД ĐŸĐŽĐœĐŸĐłĐŸ ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžŃ Đž Đ±ĐŸĐ»Đ”Đ” Đ·Đ°ŃĐžĐșŃĐžŃĐŸĐČĐ°ĐœĐŸ Ń 285 паŃĐžĐ”ĐœŃĐŸĐČ (3,5 %), лДŃĐ°Đ»ŃĐœŃĐč ĐžŃŃ
ĐŸĐŽÂ â Ń 36 паŃĐžĐ”ĐœŃĐŸĐČ (0,43 %). ĐŁ 74,0 % паŃĐžĐ”ĐœŃĐŸĐČ ĐœĐ°Đ±Đ»ŃЎалО Đ”ĐŽĐžĐœŃŃĐČĐ”ĐœĐœĐŸĐ” ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐ”, Ń 14,0 % â ŃĐŸŃĐ”ŃĐ°ĐœĐžĐ” ĐŽĐČŃŃ
ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč, Ń 12,0 % â ŃĐŸŃĐ”ŃĐ°ĐœĐžĐ” ŃŃĐ”Ń
ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč Đž Đ±ĐŸĐ»Đ”Đ”. Đ ŃŃŃŃĐșŃŃŃĐ” ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč ĐżŃĐ”ĐŸĐ±Đ»Đ°ĐŽĐ°Đ»Đž паŃДз ĐșĐžŃĐ”ŃĐœĐžĐșĐ° (25,57 %), ĐżĐœĐ”ĐČĐŒĐŸĐœĐžŃ (12,1 %), ŃĐ°ĐœĐ”ĐČĐ°Ń ĐžĐœŃĐ”ĐșŃĐžŃ (12,1 %). ĐĐ°Đș лДŃĐ°Đ»ŃĐœĐŸŃŃŃ, ŃĐ°Đș Đž ŃĐ°ŃŃĐŸŃĐ° ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč ŃĐŸŃлО Ń ŃĐČДлОŃĐ”ĐœĐžĐ”ĐŒ ĐșĐŸĐ»ĐžŃĐ”ŃŃĐČĐ° ŃĐŸĐżŃŃŃŃĐČŃŃŃĐžŃ
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč. ĐĐ«ĐĐĐĐ«: ĐĐ°ĐžĐ±ĐŸĐ»Đ”Đ” ŃĐ°ŃŃŃĐ” ŃĐŸĐżŃŃŃŃĐČŃŃŃОД Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžŃ ĐČ Đ°Đ±ĐŽĐŸĐŒĐžĐœĐ°Đ»ŃĐœĐŸĐč Ń
ĐžŃŃŃгОО â гОпДŃŃĐŸĐœĐžŃĐ”ŃĐșĐ°Ń Đ±ĐŸĐ»Đ”Đ·ĐœŃ, Ń
ŃĐŸĐœĐžŃĐ”ŃĐșĐ°Ń ŃĐ”ŃĐŽĐ”ŃĐœĐ°Ń ĐœĐ”ĐŽĐŸŃŃĐ°ŃĐŸŃĐœĐŸŃŃŃ, ĐžŃĐ”ĐŒĐžŃĐ”ŃĐșĐ°Ń Đ±ĐŸĐ»Đ”Đ·ĐœŃ ŃĐ”ŃĐŽŃĐ°, ŃĐ°Ń
Đ°ŃĐœŃĐč ĐŽĐžĐ°Đ±Đ”Ń Đž ĐœĐ°ŃŃŃĐ”ĐœĐžĐ” ŃĐ”ŃĐŽĐ”ŃĐœĐŸĐłĐŸ ŃĐžŃĐŒĐ°. ЧаŃŃĐŸŃĐ° ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃŃ
ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč ŃĐŸŃŃĐ°ĐČОла 3,5 %, лДŃĐ°Đ»ŃĐœĐŸŃŃŃ â 0,43 %; ĐżŃĐž ŃŃĐŸĐŒ ĐœĐ°ĐžĐ±ĐŸĐ»Đ”Đ” ŃĐ°ŃŃŃĐŒĐž ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžŃĐŒĐž бŃлО паŃДз ĐșĐžŃĐ”ŃĐœĐžĐșĐ°, ŃĐ°ĐœĐ”ĐČĐ°Ń ĐžĐœŃĐ”ĐșŃĐžŃ Đž ĐżĐœĐ”ĐČĐŒĐŸĐœĐžŃ
Knowledge Base, Exporting Activities, Innovation Openness and Innovation Performance: A SEM Approach Towards a Unifying Framework
In this paper we demonstrate the complexity that regulates the innovation-exports nexus. In particular we argue that innovation and exports should be treated as latent variables in order to account for as many facets possible thus, accounting for multifaceted heterogeneity. In this context, the role of innovation openness ought to be highlighted within a unified framework, as it is considered an additional activity of firms' knowledge creation strategy. In this line, innovation and exporting orientation are ruled by the firms' strategic mix comprised of internal knowledge creation processes and the diversity of innovation openness. Theoretical and empirical links between these major components are identified and measured employing a Structural Equation Modelling (SEM) approach on a sample of Greek R&D-active manufacturing firms. Empirical findings corroborate the complexity of relationships and indicate that the firms' knowledge base and open innovation strategy regulate via complementary and substitution relationships firms' innovation and export performance
ĐĐŸĐŽĐ”Đ»Ń ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐČ Đ°Đ±ĐŽĐŸĐŒĐžĐœĐ°Đ»ŃĐœĐŸĐč Ń ĐžŃŃŃгОО: ŃДзŃĐ»ŃŃĐ°ŃŃ ĐœĐ°Đ±Đ»ŃĐŽĐ°ŃДлŃĐœĐŸĐłĐŸ ĐŒĐœĐŸĐłĐŸŃĐ”ĐœŃŃĐŸĐČĐŸĐłĐŸ ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ
ĐĐйУĐĐĐŹĐĐХйЏ: ĐДЎŃŃДД ĐŒĐ”ŃŃĐŸ ĐČ ŃŃŃŃĐșŃŃŃĐ” ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃŃ
ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč Đ·Đ°ĐœĐžĐŒĐ°Đ”Ń ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐ°Ń ĐżĐœĐ”ĐČĐŒĐŸĐœĐžŃ. ĐŁŃĐžŃŃĐČĐ°Ń ŃĐ°ŃĐżŃĐŸŃŃŃĐ°ĐœĐ”ĐœĐœĐŸŃŃŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž О ŃĐŸŃŃ ŃĐžŃла Ń
ĐžŃŃŃгОŃĐ”ŃĐșĐžŃ
ĐżŃĐŸŃДЎŃŃ, ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžĐ” ДД ŃĐ°Đ·ĐČĐžŃĐžŃ ŃĐČĐ»ŃĐ”ŃŃŃ Đ°ĐșŃŃĐ°Đ»ŃĐœĐŸĐč Đ·Đ°ĐŽĐ°ŃĐ”Đč, ĐżĐŸĐ·ĐČĐŸĐ»ŃŃŃĐ”Đč ĐżŃĐžĐœŃŃŃ ĐŒĐ”ŃŃ ĐżĐŸ ŃĐœĐžĐ¶Đ”ĐœĐžŃ ŃĐ°ŃŃĐŸŃŃ Đ”Đ” ĐČĐŸĐ·ĐœĐžĐșĐœĐŸĐČĐ”ĐœĐžŃ, ĐżŃŃĐ”ĐŒ ĐŸĐżŃĐžĐŒĐžĐ·Đ°ŃОО пДŃĐžĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐłĐŸ пДŃĐžĐŸĐŽĐ°. ĐĐ”ŃĐŒĐŸŃŃŃ ĐœĐ° ŃĐČĐŸŃ ŃĐ”ĐœĐœĐŸŃŃŃ, ŃŃŃĐ”ŃŃĐČŃŃŃОД ŃĐșĐ°Đ»Ń ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐœĐ” ĐŸĐ±Đ”ŃпДŃĐžĐČĐ°ŃŃ ĐŸŃĐ”ŃĐ”ŃŃĐČĐ”ĐœĐœŃŃ
ŃпДŃОалОŃŃĐŸĐČ ĐœĐ°ĐŽĐ”Đ¶ĐœŃĐŒ ĐžÂ ĐżĐŸŃŃĐŸŃĐœĐœŃĐŒ ĐŒĐ”ŃĐŸĐŽĐŸĐŒ, ŃÂ ĐżĐŸĐŒĐŸŃŃŃ ĐșĐŸŃĐŸŃĐŸĐłĐŸ ĐŒĐŸĐ¶ĐœĐŸ ŃŃŃĐ°ŃĐžŃĐžŃĐžŃĐŸĐČĐ°ŃŃ ŃĐžŃĐș ŃĐ°Đ·ĐČĐžŃĐžŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐČÂ ĐœĐ°ŃĐ”Đč ĐżĐŸĐżŃĐ»ŃŃОО. ĐŠĐĐĐŹ ĐĐĄĐĄĐĐĐĐĐĐĐĐĐŻ: ŃĐ°Đ·ŃĐ°Đ±ĐŸŃĐșĐ° ĐŒĐŸĐŽĐ”Đ»Đž ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐœĐ° ĐŸŃĐœĐŸĐČĐ” ĐČŃŃĐČĐ»Đ”ĐœĐžŃ ŃĐ°ĐșŃĐŸŃĐŸĐČ ŃĐžŃĐșĐ° ДД ŃĐ°Đ·ĐČĐžŃĐžŃ. ĐĐĐąĐĐ ĐĐĐĐ« Đ ĐĐĐąĐĐĐ«: ĐĐœĐŸĐłĐŸŃĐ”ĐœŃŃĐŸĐČĐŸĐ” ĐżŃĐŸŃпДĐșŃĐžĐČĐœĐŸĐ” ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐ”, 6844 паŃĐžĐ”ĐœŃĐ° ŃŃĐ°ŃŃĐ” 18 лДŃ, ĐżĐŸĐŽĐČĐ”ŃгаŃŃОДŃŃ ĐżĐ»Đ°ĐœĐŸĐČŃĐŒ ĐŸĐżĐ”ŃĐ°ŃĐžĐČĐœŃĐŒ ĐČĐŒĐ”ŃĐ°ŃДлŃŃŃĐČĐ°ĐŒ ĐœĐ° ĐŸŃĐłĐ°ĐœĐ°Ń
бŃŃŃĐœĐŸĐč ĐżĐŸĐ»ĐŸŃŃĐž. ĐŃĐ”ĐœĐžĐČалО 30-ĐŽĐœĐ”ĐČĐœŃŃ Đ»Đ”ŃĐ°Đ»ŃĐœĐŸŃŃŃ ĐžÂ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃŃ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžŃ. ĐĐ° пДŃĐČĐŸĐŒ ŃŃапД ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ ĐżŃĐŸĐČĐŸĐŽĐžĐ»ĐŸŃŃ ŃŃĐ°ĐČĐœĐ”ĐœĐžĐ” ĐŒĐ”Đ¶ĐŽŃ ĐłŃŃĐżĐżĐŸĐč ŃÂ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐ”Đč О гŃŃĐżĐżĐŸĐč бДз ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐžŃŃ
ĐŸĐŽĐœŃŃ
ĐŽĐ°ĐœĐœŃŃ
паŃĐžĐ”ĐœŃĐŸĐČ, Đ°Â ŃĐ°ĐșжД ŃĐ°ĐșŃĐŸŃĐŸĐČ, ŃĐČŃĐ·Đ°ĐœĐœŃŃ
ŃÂ ĐŸĐżĐ”ŃĐ°ŃОДĐč ĐžÂ Đ°ĐœĐ”ŃŃДзОДĐč. ĐĐ° ĐČŃĐŸŃĐŸĐŒ ŃŃапД ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ ĐżŃĐŸĐČĐŸĐŽĐžĐ»ŃŃ Đ»ĐŸĐłĐžŃŃĐžŃĐ”ŃĐșĐžĐč ŃДгŃĐ”ŃŃĐžĐŸĐœĐœŃĐč Đ°ĐœĐ°Đ»ĐžĐ· ĐŽĐ»Ń ĐŸŃĐ”ĐœĐșĐž ĐČĐșлаЎа ŃĐ°ĐșŃĐŸŃĐŸĐČ ĐČ ŃĐ°Đ·ĐČĐžŃОД ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž. ĐĐ° ŃŃĐ”ŃŃĐ”ĐŒ ŃŃапД ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ ĐČŃĐżĐŸĐ»ĐœŃĐ»ĐŸŃŃ ĐżĐŸŃŃŃĐŸĐ”ĐœĐžĐ” ĐŒĐŸĐŽĐ”Đ»Đž ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐżĐŸ ĐŽĐ°ĐœĐœŃĐŒ ĐŒĐœĐŸĐłĐŸĐŒĐ”ŃĐœĐŸĐłĐŸ Đ»ĐŸĐłĐžŃŃĐžŃĐ”ŃĐșĐŸĐłĐŸ ŃДгŃĐ”ŃŃĐžĐŸĐœĐœĐŸĐłĐŸ Đ°ĐœĐ°Đ»ĐžĐ·Đ°. ĐĐ° Đ·Đ°ĐșĐ»ŃŃĐžŃДлŃĐœĐŸĐŒ ŃŃапД ĐżŃĐŸĐžĐ·ĐČĐŸĐŽĐžĐ»ĐŸŃŃ ŃŃĐ°ĐČĐœĐ”ĐœĐžĐ” ĐżĐŸĐ»ŃŃĐ”ĐœĐœĐŸĐč ĐŒĐŸĐŽĐ”Đ»Đž ŃÂ ĐŒĐŸĐŽĐ”Đ»ŃĐŒĐž ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžŃ ĐŽŃŃгОŃ
Đ°ĐČŃĐŸŃĐŸĐČ, ĐČŃŃŃĐ”ŃĐ°ŃŃĐžŃ
ŃŃ ĐČÂ ĐŒĐžŃĐŸĐČĐŸĐč лОŃĐ”ŃĐ°ŃŃŃĐ”. Đ ĐĐĐŁĐĐŹĐąĐйЫ: ĐĐœĐ”ĐČĐŒĐŸĐœĐžŃ ĐČŃŃĐČĐ»Đ”ĐœĐ° Ń 53 паŃĐžĐ”ĐœŃĐŸĐČ (0,77 %). ĐĐ”ŃĐ°Đ»ŃĐœŃĐč ĐžŃŃ
ĐŸĐŽ ĐœĐ°Đ±Đ»ŃĐŽĐ°Đ»ŃŃ Ń 39 паŃĐžĐ”ĐœŃĐŸĐČ: Ń паŃĐžĐ”ĐœŃĐŸĐČ ŃÂ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐ”Đč ĐČ 15 ŃĐ»ŃŃĐ°ŃŃ
(28,3 %), а бДз ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐžÂ â ĐČ 24 ŃĐ»ŃŃĐ°ŃŃ
(0,4 %). Đ Đ”ŃŃĐŸŃпДĐșŃĐžĐČĐœĐŸ Ń ŃŃĐ”ŃĐŸĐŒ ĐżĐŸĐ»ŃŃĐ”ĐœĐœĐŸĐč ĐŒĐŸĐŽĐ”Đ»Đž Đș ĐłŃŃппД ĐČŃŃĐŸĐșĐŸĐłĐŸ ŃĐžŃĐșĐ° ŃĐ°Đ·ĐČĐžŃĐžŃ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž бŃлО ĐŸŃĐœĐ”ŃĐ”ĐœŃ 933 паŃĐžĐ”ĐœŃĐ°, ŃĐ°ŃŃĐŸŃĐ° ŃĐ°Đ·ĐČĐžŃĐžŃ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ŃĐŸŃŃĐ°ĐČĐ»Ńла 4,5 %. Đ гŃŃппД ĐœĐžĐ·ĐșĐŸĐłĐŸ ŃĐžŃĐșĐ° ŃĐ°Đ·ĐČĐžŃĐžŃ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐžÂ â 5911 паŃĐžĐ”ĐœŃĐŸĐČ, ŃĐ°ŃŃĐŸŃĐ° ŃĐ°Đ·ĐČĐžŃĐžŃ ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ŃĐŸŃŃĐ°ĐČĐ»Ńла 0,19 %. ĐĐ«ĐĐĐĐ«: ĐŃŃĐČĐ»Đ”ĐœŃ ĐČĐŸŃĐ”ĐŒŃ ĐœĐ”Đ·Đ°ĐČĐžŃĐžĐŒŃŃ
пДŃĐ”ĐŒĐ”ĐœĐœŃŃ
, ŃĐČŃĐ·Đ°ĐœĐœŃŃ
ŃÂ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐ”Đč: ЎлОŃДлŃĐœĐŸŃŃŃ ĐŸĐżĐ”ŃĐ°ŃОО, ĐșŃŃĐ”ĐœĐžĐ”, ĐżĐŸĐ»ĐœĐ°Ń ŃŃĐœĐșŃĐžĐŸĐœĐ°Đ»ŃĐœĐ°Ń Đ·Đ°ĐČĐžŃĐžĐŒĐŸŃŃŃ, пДŃĐžĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐ°Ń Đ°ĐœĐ”ĐŒĐžŃ, ŃŃДбŃŃŃĐ°Ń ĐżŃĐžĐŒĐ”ĐœĐ”ĐœĐžŃ ĐżŃДпаŃĐ°ŃĐŸĐČ Đ¶Đ”Đ»Đ”Đ·Đ°, ĐžĐœŃŃĐ°ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐ” ĐżŃĐžĐŒĐ”ĐœĐ”ĐœĐžĐ” ĐČĐ°Đ·ĐŸĐżŃĐ”ŃŃĐŸŃĐŸĐČ, III ŃŃĐœĐșŃĐžĐŸĐœĐ°Đ»ŃĐœŃĐč ĐșлаŃŃ ĐżĐŸ ĐșлаŃŃĐžŃĐžĐșĐ°ŃОО ĐĐŒĐ”ŃĐžĐșĐ°ĐœŃĐșĐŸĐłĐŸ ĐŸĐ±ŃĐ”ŃŃĐČĐ° Đ°ĐœĐ”ŃŃĐ”Đ·ĐžĐŸĐ»ĐŸĐłĐŸĐČ, ĐżŃĐžĐŒĐ”ĐœĐ”ĐœĐžĐ” бŃĐŸĐœŃ
ĐŸĐŽĐžĐ»Đ°ŃĐžŃŃŃŃĐžŃ
ĐżŃДпаŃĐ°ŃĐŸĐČ ĐżĐŸ ĐżĐŸĐČĐŸĐŽŃ Ń
ŃĐŸĐœĐžŃĐ”ŃĐșĐŸĐč ĐŸĐ±ŃŃŃŃĐșŃĐžĐČĐœĐŸĐč Đ±ĐŸĐ»Đ”Đ·ĐœĐž лДгĐșĐžŃ
, ĐČŃŃĐŸĐșĐžĐč ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœŃĐč ŃĐžŃĐș. ĐĐŸĐŽĐ”Đ»Ń ĐżŃĐŸĐłĐœĐŸĐ·ĐžŃĐŸĐČĐ°ĐœĐžŃ ĐżĐŸŃĐ»Đ”ĐŸĐżĐ”ŃĐ°ŃĐžĐŸĐœĐœĐŸĐč ĐżĐœĐ”ĐČĐŒĐŸĐœĐžĐž ĐžĐŒĐ”Đ”Ń ĐŸŃлОŃĐœŃŃ ĐżŃĐŸĐłĐœĐŸŃŃĐžŃĐ”ŃĐșŃŃ Đ·ĐœĐ°ŃĐžĐŒĐŸŃŃŃ (AUROC = 0,904)
Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer
Background: Febrile neutropenia is a frequently occurring and occasionally life-threatening complication of treatment for childhood cancer. Many biomarkers have been proposed as predictors of adverse events. We aimed to undertake a systematic review and meta-analysis to summarize evidence on the discriminatory ability of initial serum biomarkers of febrile neutropenic episodes in children and young people.
Methods: This review was conducted in accordance with the Center for Reviews and Dissemination Methods, using three random effects models to undertake meta-analysis. It was registered with the HTA Registry of systematic reviews, CRD32009100485.
Results: We found that 25 studies exploring 14 different biomarkers were assessed in 3,585 episodes of febrile neutropenia. C-reactive protein (CRP), pro-calcitonin (PCT), and interleukin-6 (IL6) were subject to quantitative meta-analysis, and revealed huge inconsistencies and heterogeneity in the studies included in this review. Only CRP has been evaluated in assessing its value over the predictive value of simple clinical decision rules.
Conclusions: The limited data available describing the predictive value of biomarkers in the setting of pediatric febrile neutropenia mean firm conclusions cannot yet be reached, although the use of IL6, IL8 and procalcitonin warrant further study
Potential therapeutic applications of microbial surface-activecompounds
Numerous investigations of microbial surface-active compounds or biosurfactants over the past two decades have led to the discovery of many interesting physicochemical and biological properties including antimicrobial, anti-biofilm and therapeutic among many other pharmaceutical and medical applications. Microbial control and inhibition strategies involving the use of antibiotics are becoming continually challenged due to the emergence of resistant strains mostly embedded within biofilm formations that are difficult to eradicate. Different aspects of antimicrobial and anti-biofilm control are becoming issues of increasing importance in clinical, hygiene, therapeutic and other applications. Biosurfactants research has resulted in increasing interest into their ability to inhibit microbial activity and disperse microbial biofilms in addition to being mostly nontoxic and stable at extremes conditions. Some biosurfactants are now in use in clinical, food and environmental fields, whilst others remain under investigation and development. The dispersal properties of biosurfactants have been shown to rival that of conventional inhibitory agents against bacterial, fungal and yeast biofilms as well as viral membrane structures. This presents them as potential candidates for future uses in new generations of antimicrobial agents or as adjuvants to other antibiotics and use as preservatives for microbial suppression and eradication strategies
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events
- âŠ